(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






FedEx Q4 Earnings Preview: Analysts' Targets for Atlanticus, GigaCloud, Bio-Rad Labs, EnerSys

  • June 17th, 2023
  • 241 views

FedEx Corp. (NYSE: FDX), a global logistics and delivery services company, is set to release its fourth-quarter fiscal 2023 financial results on Tuesday, June 20, 2023, after the market closes. 

Analysts are anticipating a consensus earnings per share (EPS) of $4.90 on revenue of $22.77 billion for the quarter.

On Friday, $FDX closed at $233.46, reflecting a decline of $2.98 (-1.26%). 

Atlanticus Holdings Corporation (Nasdaq: ATLC), a financial services company specializing in providing credit and related financial services, received coverage initiation from Jefferies with a Buy rating and a price target of $50.

Despite $ATLC closing at $38.80 on Friday, the price target suggests a potential upside of $11.20 or 28.87%, according to the investment advisory firm's analysis.

GigaCloud Technology Inc. (Nasdaq: GCT), a technology company offering cloud computing and data management solutions, had its coverage initiated by Roth MKM with a Buy rating and a price target of $13.

While $GCT closed at $8.08 on Friday, the announced price target implies a potential upside of $4.92 or 60.89%, based on the investment firm's perspective.

Bio-Rad Laboratories, Inc. (NYSE: BIO), a leading provider of life science research and clinical diagnostic products, received coverage initiation from Wells Fargo with an Overweight rating and a price target of $550.

Based on Friday's closing price of $376.56, the newly announced price target indicates a potential upside of $173.44 or 46.04% for $BIO, as per the analysis of the financial services firm.

EnerSys (NYSE: ENS), a global leader in stored energy solutions for industrial applications, had its Outperform rating maintained by Oppenheimer, accompanied by a price target increase from $110 to $119.

With $ENS closing at $104.40 on Friday, the adjusted price target implies a potential upside of $14.60 or 13.99%, according to the view of the investment management firm.

The potential upsides mentioned are based on the viewpoints of brokerage firms and analysts. It is crucial to acknowledge that actual potential upsides may differ, and investors are encouraged to conduct comprehensive research and analysis of their own before making any investment decisions.

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)

Social Shares

Post Your Comments


Warning: Undefined array key "hashid" in /var/www/html/subs/visit_counter.php on line 13